R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy

Sanofi SA (NASDAQ:SNY) is one of the best dividend stocks yielding at least 5% to buy according to hedge funds.

On June 22, Sanofi SA (NASDAQ:SNY) announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President and Global Head of Research & Development Pharma, effective September 1. Based in Paris, Fontoura will join Sanofi’s Executive Committee and report directly to CEO Belen Garijo.

As head of R&D Pharma, Fontoura will oversee Sanofi’s end‑to‑end innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. His mandate includes advancing a differentiated pipeline and accelerating the delivery of transformative medicines to patients worldwide. He succeeds Dr. Houman Ashrafian, who is leaving the company to pursue new opportunities.

Fontoura brings more than 25 years of experience across academic medicine, translational science, clinical development, and pharmaceutical innovation. His appointment comes at a pivotal time for Sanofi, which is driving an R&D transformation and progressing a pipeline of new medicines across multiple therapeutic areas.

Meanwhile, on June 22, MacroGenics confirmed it is entitled to $24.5 million in regulatory milestone payments from Sanofi. The payment follows the FDA accelerated approval of TZIELD (teplizumab-mzwv) to delay the decline in endogenous insulin production in children.

Sanofi SA (NASDAQ:SNY) is a global biopharmaceutical company that researches, develops, and manufactures prescription medicines and vaccines. It focuses heavily on the immune system to treat complex conditions, including immunology, rare diseases, and oncology, and is also a leading worldwide supplier of vaccines for polio, influenza, and RSV.

READ NEXT: 8 Mining Stocks with the Highest Dividends and 10 UK Stocks with the Highest Dividends.

Disclosure: None. Follow Insider Monkey on Google News.